MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First...












